On November 1st, a new mode of medication is expected to help combat the “aggressive” form of breast cancer.
The American laboratory Gilead produces “Trodelvy”, a treatment that helps curb the so-called “triple-negative” breast cancer. This form of cancer resists current medical treatment and affects nearly 9,000 women.
Trodelvy combines antibodies and chemotherapy to fight the disease. Last year, this treatment, which was previously prescribed only on a nominative basis, was extended to all patients suffering from “triple-negative” breast cancer.
In this context, on Tuesday, October 5th, during a meeting at the National Assembly, Olivier Véran confirmed the release of the drug starting from November 1, 2021.
The evaluation of the treatment has been accelerated to make it quickly available on the market. As a reminder, it benefits from an early authorization allowing it to be administered. However, while the High Health Authority has authorized “Trodelvy”, the medicines agency has not yet given its opinion.
